Business
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today highlighted new preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225) at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat being held October 23 – 25, 2025 in Carlsbad, CA.
About this update from Actinium Pharmaceuticals, Inc. (delaware)
[{"type":"text","content":"- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology withcontinued expression following androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy, enabling potent activity independent of PSMA expression","length":252,"tagName":"p","attribs":{}},{"type":"text","content":"- ATNM-400 demonstrated superior efficacy over PSMA-targeted radioligand therapy(177Lu-PSMA-617 and 225Ac-PSMA-617) with enhanced tumor control and prolonged survival in low-PSMA and treatment-resistant models","length":216,"tagName":"p","attribs":{}},{"type":"text","content":"- Demonstrated durable anti-tumor responses, exceeding those achieved with the ARPI enzalutamide","length":102,"tagName":"p","attribs":{}},{"type":"text","content":"- Combination of ATNM-400 with enzalutamide achieved complete tumor regressionin 40% of prostate cancer-bearing animals, demonstrating strong mechanistic synergy with AR pathway inhibition","length":195,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Oct. 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today highlighted new preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225) at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat being held October 23 – 25, 2025 in Carlsbad, CA.","length":478,"tagName":"p"},{"type":"text","content":"ATNM-400, which targets a non-PSMA antigen associated with prostate cancer progression and treatment resistance, demonstrated superior tumor control and improved overall survival compared with the active agents in key standard-of-care therapies including enzalutamide (the active agent in Xtandi®, Astellas/Pfizer) and 177Lu-PSMA-617 (the active agent in Pluvicto®, Novartis), as well as 225Ac-PSMA-617 across multiple preclinical prostate cancer models.","length":454,"tagName":"p","attribs":{}},{"type":"text","content":"These data further reinforce ATNM-400's potential as a paradigm changing, PSMA-independent Ac-225 alpha radiotherapy, offering opportunities for use as a monotherapy, in combination regimens, and in patients relapsing after ARPI or PSMA-directed treatments. ATNM-400 data has ...